Clinical study of tolcapone for transthyretin (TTR)-type cerebral amyloid angiopathy in patients with familial amyloid polyneuropahty (FAP)
Not Applicable
- Conditions
- Familial amyloid polyneuropahty
- Registration Number
- JPRN-UMIN000030341
- Lead Sponsor
- Shinshu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
Asymptomatic mutation carriers Contraindication for tolcapone An ALT or AST measurement > 2 times the ULN (Upper Limit of Normal) Treatment with NSAID or a known TTR binder within the last 4 weeks Stage 3 disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method stability ratio of CSF TTR tetramer
- Secondary Outcome Measures
Name Time Method